Evidence map›Paper›PMID 36575396›Full record

ArticleBMC bioinformatics2022

A novel glycosylation-related gene signature predicts survival in patients with lung adenocarcinoma.

Jin-Xiao Liang, Qian Chen, Wei Gao, Da Chen, Xin-Yu Qian, Jin-Qiao Bi, Xing-Chen Lin, Bing-Bing Han, Jin-Shi Liu

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Translational cancer research · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jin-Xiao LiangDepartment of Oncological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 of Banshan East Road, Hangzhou, 310022, Zhejiang Province, Republic of China.
Qian ChenDepartment of Oncological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 of Banshan East Road, Hangzhou, 310022, Zhejiang Province, Republic of China.
Wei GaoSchool of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China.
Da ChenDepartment of Oncological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 of Banshan East Road, Hangzhou, 310022, Zhejiang Province, Republic of China.
Xin-Yu QianSchool of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China.
Jin-Qiao BiSchool of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China.
Xing-Chen LinSchool of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China.
Bing-Bing HanSchool of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China.
Jin-Shi LiuDepartment of Oncological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No. 1 of Banshan East Road, Hangzhou, 310022, Zhejiang Province, Republic of China. yefeng9725boy@163.com.
Zhejiang University · CNZhejiang Cancer Hospital · CNChinese Academy of Sciences · CNUniversity of Chinese Academy of Sciences · CN

Funding

Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2020KY083Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2020KY680Zhejiang Province Public Welfare Technology Application Research Project (Animal Experiment Project) LGD20H160002
6 · The paper itself

Abstract

backgroundLung adenocarcinoma (LUAD) is the most common malignant tumor that seriously affects human health. Previous studies have indicated that abnormal levels of glycosylation promote progression and poor prognosis of lung cancer. Thus, the present study aimed to explore the prognostic signature related to glycosyltransferases (GTs) for LUAD.

methodsThe gene expression profiles were obtained from The Cancer Genome Atlas (TCGA) database, and GTs were obtained from the GlycomeDB database. Differentially expressed GTs-related genes (DGTs) were identified using edge package and Venn diagram. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and ingenuity pathway analysis (IPA) methods were used to investigate the biological processes of DGTs. Subsequently, Cox and Least Absolute Shrinkage and Selection Operator (LASSO) regression analyses were performed to construct a prognostic model for LUAD. Kaplan-Meier (K-M) analysis was adopted to explore the overall survival (OS) of LUAD patients. The accuracy and specificity of the prognostic model were evaluated by receiver operating characteristic analysis (ROC). In addition, single-sample gene set enrichment analysis (ssGSEA) algorithm was used to analyze the infiltrating immune cells in the tumor environment.

resultsA total of 48 DGTs were mainly enriched in the processes of glycosylation, glycoprotein biosynthetic process, glycosphingolipid biosynthesis-lacto and neolacto series, and cell-mediated immune response. Furthermore, B3GNT3, MFNG, GYLTL1B, ALG3, and GALNT13 were screened as prognostic genes to construct a risk model for LUAD, and the LUAD patients were divided into high- and low-risk groups. K-M curve suggested that patients with a high-risk score had shorter OS than those with a low-risk score. The ROC analysis demonstrated that the risk model efficiently diagnoses LUAD. Additionally, the proportion of infiltrating aDCs (p < 0.05) and Tgds (p < 0.01) was higher in the high-risk group than in the low-risk group. Spearman's correlation analysis manifested that the prognostic genes (MFNG and ALG3) were significantly correlated with infiltrating immune cells.

conclusionIn summary, this study established a novel GTs-related risk model for the prognosis of LUAD patients, providing new therapeutic targets for LUAD. However, the biological role of glycosylation-related genes in LUAD needs to be explored further.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAlgorithmsGlycosylationHumansMannosyltransferasesRisk FactorsALG3 protein, humanMannosyltransferasesGlycosyltransferases (GTs)Immune cellsLung adenocarcinoma (LUAD)Prognosis

Identifiers

PMID36575396
PMCPMC9793550
OpenAlexW4313250662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.